Managing acute osteoporotic vertebral fractures with calcitonin

Canadian Family Physician

Volumn 44, Issue OCT., 1998, Pages 2160-2166

  Maksymowych, Walter P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ZAFIRLUKAST;

ANALGESIC ACTIVITY; CLINICAL TRIAL; DATA BASE; DRUG EFFECT; FLUSHING; GENERAL PRACTICE; HUMAN; INTRANASAL DRUG ADMINISTRATION; LABORATORY TEST; META ANALYSIS; MOBILIZATION; NAUSEA; OSTEOPOROSIS; PAIN; RADIODIAGNOSIS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VERTEBRA FRACTURE;

ACUTE DISEASE; ADMINISTRATION, INTRANASAL; CALCITONIN; FAMILY PRACTICE; HUMANS; INJECTIONS, SUBCUTANEOUS; OSTEOPOROSIS; PAIN; PAIN MEASUREMENT; RESEARCH DESIGN; SPINAL FRACTURES; TIME FACTORS;

EID: 0031768511     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-8.
2. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
3. Lyritis GP, Mayasis B, Taskalakos N, Lambropoulos A, Gazi S, Karachalios TH, et al. The natural history of the osteoporotic vertebral fracture. Clin Rheumatol 1989;9(Suppl 2):66-9.
4. Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. Can Med Assoc J 1996;155:1113-33.
5. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
6. Lukert BP. Vertebral compression fractures: how to manage pain, avoid disability. Geriatrics 1994;49:22-6.
7. Gennari C, Chierichetti SM, Gonnelli S. Analgesic activity and side effects of different calcitonins in man. In: Pecile A, editor. Calcitonin 1984 - chemistry, physiology, pharmacology and clinical aspects. Amsterdam: Excerpta Medica; 1985. p. 183-8.
8. Spaventi S, Vibanec D. Effect of calcitonin on the skeleton and bone pain in patients with osteolytic metastases. Acta Med Yugosl 1987;41:32-42.
9. Doury P, Patin S. Le traitement de l'algodystrophy par la thyrocalcitonine. À propos de 60 observations. Rheumatologie 1980;22:113-8.
10. Gennari C. Calcitonin in osteogenic pain. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis. Copenhagen: Osteopress; 1987. p. 1256-61.
11. Wallach S, Cohn SA, Atkins HL, Ellis KJ, Kohberger R, Aloia JF, et al. Effects of salmon calcitonin on skeletal mass in osteoporosis. Curr Ther Res 1977;22:556-72.
12. Franceschini R, Bottaro P, Panopoulos C, Messina V. Long-term treatment with salmon calcitonin in postmenopausal osteoporosis. Curr Ther Res 1983;34:795-800.
13. Zorzin L, Capone M. Post-menopausal osteoporosis: therapeutic and side-effects of different calcitonins. Curr Ther Res 1984;36:473-82.
14. Palmieri GMA, Pitcock JA, Brown P, et al. Effect of calcitonin and vitamin D in osteoporosis. Calcif Tissue Int 1991;49:369-72.
15. Minaire P, Mallet E, Levernieux J, Schoutens A, Attali G, Caulin F. Immobilization bone loss: preventive effect of calcitonin in several clinical modules. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis. Copenhagen: Osteopress; 1987. p. 603-6.
16. Attali G, Levernieux J, Caulin F. Recent crush fracture syndrome. Effect of salmon calcitonin. Results of three double-blind studies and one open study. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis. Copenhagen: Osteopress; 1987. p. 930-2.
17. Arinoviche R, Arriagada M, Jacobelli S, Massardo L, revero S, Aris H, et al. Calcitonin in acute pain due to vertebral fractures in osteoporosis. Rev Med Chile 1987;115:1039-43.
18. Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991;49:369-72.
19. Ljunghall S, Gardsell P, Johnell O, Larsson K, Lindh E, Obrant K, et al. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int 1991;49:17-9.
20. Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989;11:205-9.
21. Combe B, Cohen C, Aubin F. Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int 1997;61:10-5.
22. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987;33:35-9.
23. Siminoski K, Josse RG. Calcitonin in the treatment of osteoporosis. Can Med Assoc J 1996;155:962-5.
24. Laurian L, Oberman Z, Graf E, Gilad S, Hoerer E, Simantov R. Calcitonin-induced increase in ACTH, β-endorphin, and cortisol secretion. Horm Metab Res 1986;18:268-71.
25. Fabbri A, Fraioli F, Pert CB, Pert A. Calcitonin receptors in the mesencephalon mediate its analgesic actions: autoradiographic behavioral analyses. Brain Res 1985;343:205-15.
26. Gennari C, Avioli LV. Calcitonin therapy in osteoporosis. In: Osteoporotic syndrome 2, Philadelphia: Grune & Stratton; 1987. p. 121-42.
27. Paavolainen P, Taivainen T, Michelsson J-E, Lalla M, Penttinen R. Calcitonin and fracture healing. An experimental study on rats. J Orthop Res 1989;7:100-6.